9
Sep
2016

Reflections from Yellowstone, EpiPen’s Foul Aftermath, and Saunders Steps Up

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
 

You may also like

Merck Buys Cidara, Abbott Acquires Exact, & Function Flies
Pfizer Grabs Metsera, Merck Delivers Oral PCSK9, & Kura Wins 1st FDA OK
Novo-Pfizer Bidding War, BillionToOne IPO, & FDA Turmoil
Novartis Acquires Avidity for $12B, Novo Stiff-Arms Pfizer & Intellia Woes